Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company codeSLGL
Company nameSol Gel Technologies Ltd
IPO dateFeb 01, 2018
Founded at1997
CEO- -
Number of employees34
Security typeOrdinary Share
Fiscal year-endFeb 01
AddressGolda Meir 7
CityNESS-ZIONA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code- -
Phone97289313433
Websitehttp://www.sol-gel.com
Company codeSLGL
IPO dateFeb 01, 2018
Founded at1997
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data